A court filing by Massachusetts Attorney General Maura Healey on Tuesday revealed new information about the inner workings of Purdue Pharma and its controlling Sackler family as they marketed OxyContin over the past two decades, including harsh statements by executives that point to a strategy of blaming drug users for addiction to the painkiller.
Medical device maker Greatbatch Ltd. received a $22 million damages award Monday following a six-day trial in Delaware federal court over three pacemaker technology patents infringed by AVX Corp., replacing a 2016 jury decision that awarded it $37.5 million.
Navigators Specialty Insurance Co. has asked a California federal court to affirm that it doesn't have to defend or indemnify Depomed Inc.'s successor in more than three dozen suits over the drugmaker's role in the opioid crisis, saying the policies don't cover opioid-related injuries and "allegedly intentional wrongdoing."
The head of the U.S. Food and Drug Administration on Tuesday said on Twitter that 400 agency staff members are being called back from furlough to carry out high-risk inspections for food, drugs and medical devices.
A Delaware Chancery Court judge reduced an award of attorneys' fees requested by plaintiffs' counsel Tuesday in a shareholder merger suit alleging conflict of interest against the directors of medical technology company Miramar Labs Inc. before approving a $410,000 cash settlement.
An Israeli medical device company and a California-based maker of animated television commercials joined the pipeline for initial public offerings Monday with filings totaling $47 million, despite a lengthening government shutdown that makes it uncertain when the deals will price.
Akorn Inc. told an Illinois federal judge on Monday that a shareholder’s consolidated derivative suit claiming the pharmaceutical company’s falsified regulatory submissions sunk a multibillion-dollar merger and tanked Akorn’s share price doesn’t offer allegations to support a securities claim and must be tossed.
U.S. attorney general nominee William Barr on Tuesday walked back previous comments about the False Claims Act's whistleblower provisions' being an "abomination" and unconstitutional, saying he would "diligently enforce" the law if confirmed to lead the U.S. Department of Justice.
Lewis Brisbois Bisgaard & Smith LLP is significantly beefing up the ranks of its Philadelphia-area office with a team of eight attorneys, including a new co-chair and co-vice chair for its life sciences practice, brought on board from Segal McCambridge Singer & Mahoney Ltd.
Latham & Watkins LLP was able to block Nevada from using Alvogen Inc.'s drug in a lethal injection, secured orphan drug exclusivity for Eagle Pharmaceuticals Inc. after a large fight with the FDA and advised a key generic-drug industry merger, earning the firm a spot among Law360's Life Sciences Groups of the Year.
Edwards Lifesciences Corp. has agreed to pay Boston Scientific Corp. $180 million to settle all patent litigation worldwide tied to coronary repair devices, the companies announced Tuesday.
The generic-drug industry on Monday urged the U.S. Supreme Court to turn down Maryland's attempt to revive a state law targeting price gouging, arguing that Maryland is attempting to skirt a "bedrock principle of federalism" by regulating what happens in other states.
A consumer who claims Pfizer Inc. was deceitful about the "maximum strength" of its cough medicine Robitussin has asked an Illinois federal judge to certify a nationwide class of buyers who allegedly paid more for a weaker product.
A California federal judge has rejected Allergan Inc.’s high-stakes effort to make many drug compounding activities unlawful, saying he will defer to the U.S. Food and Drug Administration’s decision to allow the activities.
The Federal Circuit on Monday upheld a lower court ruling that cleared Teva Pharmaceutical Industries Ltd. and Alvogen Pine Brook LLC of patent infringement in a lawsuit over the companies’ generic versions of the colitis medication Uceris.
Baker Botts LLP can continue representing Zydus Pharmaceuticals as it pursues antitrust claims against Takeda over a heartburn medication, despite the law firm’s prior representation of Takeda’s ally in patent litigation over the same drug, a New Jersey federal judge said in a ruling made public Friday.
A cell biologist took the stand Monday in a California jury trial over allegations that Johnson & Johnson talcum-made baby powder contained asbestos that caused a dying woman’s cancer, testifying that the woman's lung tissue contains talc, which he believes came from J&J's products.
Johnson & Johnson will face off this week in Texas federal court against five plaintiffs who claimed they received defective hip implants and whose $151 million award in the first trial was tossed over misleading expert witness testimony.
Mylan told a New Jersey federal court Friday that a consumer witness should be allowed to testify in its suit accusing Celgene of stifling generic competition for two cancer drugs because Celgene already has most of the information it needs from him.
Teva Pharmaceutical Industries Ltd. and its executives doubled down on their efforts to toss securities claims from investors, who say the drugmaker engaged in a price-hike scheme and misled them about its resulting profit growth, arguing in Connecticut federal court Friday they presented no evidence.
Alternative fee agreements can help align law firm and client interests, increase efficiency and eliminate corporate extortion, among other benefits. They are the best thing to happen to the practice of law in decades, says Kelly Eisenlohr-Moul at Dinsmore & Shohl LLP.
In New Haven v. Purdue, a Connecticut state judge ruled last week that opioid manufacturers are not liable for cities' emergency and social services costs. This decision protects liability insurance from being transformed into a funding mechanism for social problems that it was not designed to cover, say Patrick Bedell and Kevin Harris of BatesCarey LLP.
Under a no-deal Brexit scenario, all provisions of EU law will no longer apply to the U.K., with potentially chaotic results for the life sciences industry. In particular, the impact on marketing authorizations could be highly disruptive, say attorneys at Latham & Watkins LLP.
Last week, the U.S. Supreme Court denied certiorari in two major False Claims Act cases, both involving the government’s knowledge or suspicion of violations allegedly resulting in knowingly false claims. Nichols Liu LLP attorneys consider the implications for the materiality standard and FCA cases going forward.
In 2018, the Trump administration took few concrete steps that will significantly impact drug prices in the near future. The most consequential ideas lack political support, while the more feasible ideas are unlikely to change much, say attorneys at Ropes & Gray LLP.
Can lawyers lead a revolution? According to "The Clamor of Lawyers: The American Revolution and Crisis in the Legal Profession" — a slim but elegant volume by Peter Charles Hoffer and Williamjames Hull Hoffer — they can and they did, says First Circuit Judge David Barron.
The U.S. Tax Court recently expanded the application of Internal Revenue Code Section 280E, disallowing certain deductions, to include an S corporation acting as a dispensary's “management” company. In response, cannabis companies may want to weigh the tax risks and potential benefits of alternate planning strategies, says Justin Hobson at Lane Powell PC.
President Donald Trump’s approach to crisis communications has changed the game enough to demand companies' consideration of a whole new set of options. John Hellerman of Hellerman Communications and Bill Pittard of KaiserDillon PLLC discuss whether corporations can successfully use similar tactics.
Lawyer-directed nonrecourse litigation funding is more likely to protect a lawyer's exercise of independent professional judgment than traditional means of litigation finance, and furthermore enables worthwhile cases that otherwise could not be funded, say Peter Jarvis and Trisha Thompson of Holland & Knight LLP.
Contrary to what the New York City Bar Association concluded in an ethics opinion last year, lawyer-directed nonrecourse commercial litigation funding does not violate New York rules on sharing fees with nonlawyers, say Peter Jarvis and Trisha Thompson of Holland & Knight LLP.